Pharmaceutical Technology's Ninth Annual Employment Survey - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology's Ninth Annual Employment Survey


Pharmaceutical Technology


Preferred employer. Pharmaceutical industry employees appear to be determined to stay in their current position. Nearly 64% said it was unlikely or very unlikely that they will change employment within the next year, an increase from the 57% reported in last year's survey. If they were to make job changes, however, nearly 71% of respondents would prefer to work in private industry over any other sector, including nonprofit agencies, academic institutions, or government.


Table V: Importance of various skills in performing daily tasks.
Essential skills and knowledge. Participants weighed in on the importance of knowledge and skills in various areas (see Table V). At the top of the list was knowledge of GMP- and GLP-related issues, with nearly 80% and 56%, respectively, rating these were very important. For the first time, the survey asked respondents to indicate the importance to their work of the US Food and Drug Administration's "Quality by Design" approach and process analytical technology (PAT) initiative. Seventy percent indicated that knowledge of PAT was important or very important in their jobs and 80% said the same about FDA's Quality by Design strategy.

FDA's continuing emphasis on its risk-based initiatives approach also is clearly influencing the pharmaceutical job environment. The questionnaire asked employees to indicate their awareness of various regulatory initiatives and weigh the effects of these initiatives on the manner in which they perform their jobs. For all three initiatives, there was an increase in the percentage of respondents who indicated they were very aware of the initiatives, with a majority (57%) now indicating they are very aware of FDA's CGMPs for the 21st Century guidance (see Table VI).


Table VI: Influence of regulatory guidelines (last year´s value in parentheses).
The most noticeable increase has been in the percentage of those stating that these initiatives have had a direct impact in the way they perform their jobs. Although 21 CFR Part 11, Electronic Records and Signatures Rule does not appear to be having an increased affect, there is a significant impact factor coming from FDA's (PAT) initiative and CGMPs guidance. Twenty-seven percent say PAT has changed the manner in which they perform their jobs, compared to only 19% who said the same last year. And, 49% now say the same for the CGMP guidance, compared to only 36% last year.

Reference

1. US Department of Labor and the US Bureau of Labor Statistics "Highlights of Women's Earnings in 2005," report 995, Sept. 2006, http://stats.bls.gov/., accessed Nov. 1, 2006.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here